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Key Points 
 With an increasing population with multimorbidity, polypharmacy and inappropriate 
medication use, are on the rise, with a greater focus is being placed on deprescribing as an 
approach to rationalize medication therapy.  
 Deprescribing, generally shown to be feasible and safe, is a process of stopping an 
inappropriate medication under the supervision of a healthcare professional.  
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 Patient preferences should play a central role in deprescribing approaches, particularly in 
patients for whom deprescribing is a preference-sensitive decision due to uncertainties about 
the benefits and harms of medications.  
Synopsis: Polypharmacy and the use of inappropriate medications has become an increasing 
problem globally. Deprescribing, or the systematic process of stopping medications that are 
harmful or no longer necessary, has gained increasing attention as a means to rationalize 
medication use. Deprescribing interventions have been shown to be generally feasible and safe; 
in the few studies in which patient preferences are assessed, such interventions also appear to be 
acceptable to patients. Qualitative studies of patient attitudes toward deprescribing suggest that 
patients are interested in reducing medications, and may have high needs for education and 
communication with their providers around deprescribing. This narrative review focuses on 
patient preferences for deprescribing and highlights practical recommendations to overcome 
barriers to deprescribing. 
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Introduction 
The prevalence of polypharmacy continues to rise in the Unites States and elsewhere 
around the world. With the global aging of the population, we are seeing a shift to a population 
with comorbidity and subsequent increased medication use. More than half of people over 65 in 
the United Stated have 3 or more chronic conditions.
1
 In the United States the population >65 
years in 2010 was 13%; by 2030 the older population is projected to reach 20%, while in other 
developed countries, older people are expected to reach >30% of the population by 2030.
2
  
 Increasing medication use is not only on the rise because of higher proportions of older 
people in the population, but also because more and more older people are exposed to 
polypharmacy. Based on recent US survey data, >90% of people 65 years and older took at least 
1 prescription medication in the prior 30 days, and 39% of older people take 5 or more regular 
medications on a chronic basis.
3
 In the UK, recent registry data shows that 24% of people 80 
years and older take 10 or more medications regularly.
4
 
 While the use of multiple medicines is necessary to treat multiple conditions, taking 
increasing numbers of medications conveys increasing risks of harm to older patients. Studies of 
polypharmacy have used different definitions and different methodologies to define the exposure 
of harmful polypharmacy, and have evaluated different outcomes as measures of harm. There is 
support to use the definition for polypharmacy as using 5 or more medications; polypharmacy in 
this regard has been shown to be harmful due to the increased risk of adverse drug events, 
adverse outcomes, and drug interactions.
5,6
 Despite inconsistencies and heterogeneities in study 
design, polypharmacy has been shown, primarily in observational studies, to be associated with 
an increased risk of adverse drug events, hospitalizations, and falls.
7
 In addition, the use of 
multiple medications is associated with an increased likelihood of important therapeutic 
4 
 
omissions through non-adherence?, such as beneficial treatments for heart failure or 
hypertension.
8
 It is unknown whether a reduction in polypharmacy results in improved patient 
outcomes, but there has been increasing interest in the reduction in medication number as a 
means to mitigate the harmful effects of polypharmacy.
7
  
 Given the increasing likelihood that healthcare providers will be faced with the 
complexity of care for adults with multimorbidity and the increasing concerns about the harms of 
polypharmacy, a greater focus has been placed on deprescribing as an approach to rationalize 
medication therapy.
9
 The purpose of this review is to briefly summarize the definition of 
deprescribing, review the process of deprescribing, to discuss the role of patient-centered care in 
guiding deprescribing interventions, and to discuss barriers and possible solutions to 
deprescribing.  
What is deprescribing? 
While many terms have been used to describe the process of stopping medications, 
including discontinuation, withdrawal, cessation, stopping, and even debridement, the universal 
use of the term “deprescribing” has been suggested moving forward to provide consistency.9,10 
While there are some variations in the definition of deprescribing, common features are 
the focus on stopping medications based on lack of benefit or increased risk. Definitions include 
the cessation of a medication no longer necessary,
11
 a process of reducing or stopping 
medications that are harmful or unnecessary,
12
 a planned process of stopping medications that 
are no longer beneficial,
13
 and a process of “tapering, stopping, discontinuing, or withdrawing 
drugs”.10 A recent systematic review and network analysis synthesized the various definitions 
and proposed the following as a definition of deprescribing: 
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Deprescribing is the process of withdrawal of an inappropriate medication, supervised 
by a health care professional with the goal of managing polypharmacy and improving 
outcomes.
10
 
The focus of this definition is on deprescribing being a process; as has been previously 
recommended, the medication use process must integrate prescribing and deprescribing.
14
 
Medications that are candidates for reduction, by this definition, are “inappropriate”, which 
could have different meanings depending on the clinical situation, and would be identified based 
on being high risk, low benefit, or both.  
Deprescribing has been shown to be feasible and generally safe, although the possibility 
of exacerbating the underlying condition being treated should not be discounted –  particularly 
when the condition involves the cardiovascular or central nervous system.
15,16
 Indeed, a recent 
systematic review of deprescribing interventions found that it was generally feasible, resulted in 
reduced medication number and minimized inappropriate medication use. 
The process of deprescribing 
Basic definitions of deprescribing highlight the fact that simply stopping a medication by 
not renewing the prescription does not capture the process required to deprescribe. Deprescribing 
requires a systematic identification of all current medications and prioritization of medications to 
be stopped, a determination of the safest means to stop medications, and a monitoring and follow 
up plan.
10,18
 The five step process, proposed by Scott, et al., is shown in Table 1.  
 
6 
 
Table 1. The process of deprescribing
19
 
Key Step Detailed Processes 
1. Ascertain all drugs the patient 
is currently taking and the 
reasons for each one 
- Ask patients (and carers) to bring all drugs (prescribed, complementary and alternative 
medicine, and over the counter) and drug delivery aids to consultation or home visit 
- Ask patients (in a nonjudgmental way) about any regularly prescribed drugs not being taken and 
if so why not (eg, too expensive, adverse effects) 
2. Consider overall risk of drug-
induced harm in individual 
patients in determining the 
required intensity of 
deprescribing intervention 
- Ascertain and assess risk according to 
 Drug factors: number of drugs (single most important predictor), use of “high-risk” drugs 
(see text), past or current toxicity 
 Patient factors: age >80 y, cognitive impairment, multiple comorbidities, substance abuse, 
multiple prescribers, past or current nonadherence 
3. Assess each drug for its 
eligibility to be discontinued 
- Identify drugs being prescribed 
 For a diagnosis that is in doubt, ie, not confirmed; highly atypical presentations; 
 For a confirmed diagnosis but in which evidence of efficacy is nonexistent  
 That confer no additional benefit after a certain period of continuous use or after a certain 
age  
7 
 
- Identify drugs prescribed to counteract adverse effects of other drugs  
- Reconsider the indications for the initial culprit drug or its substitution by an alternative drug 
with superior tolerability Identify “drugs to avoid” in older patients 
- Identify drugs contraindicated in particular patients  
- Identify drugs causing well-known adverse effects  
- Ask patient, “Since you started this medicine, has it made such a difference to how you feel that 
you would prefer to stay on it?” and consider discontinuing the drug if the response is no or 
probably not 
- Ask, “Are you still experiencing any troublesome symptoms (cough, headache, dyspepsia, etc)? 
Do you feel the medicine is still required?” 
- Consider discontinuing use of the drug if the target condition is self-limiting, mild, intermittent, 
or amenable to nondrug interventions  
- Estimate patient’s life expectancy using risk prediction tools or asking “surprise” question  
- Determine the patient’s expectations and preferences—is present-day quality of life more 
important than prolonging life or preventing future morbid events? 
- Identify drugs unlikely to confer benefit (and that may cause harm) over the patient’s remaining 
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lifespan 
- Ask the patient, “Apart from side effects, are there any other concerns you have with your 
medicines?” 
- Identify drugs that are particularly burdensome (eg, difficulty swallowing large tablets, out-of-
pocket expense, monitoring requirements) 
4. Prioritize drugs for 
discontinuation 
- Deciding the order of discontinuation of drugs may depend on integrating 3 pragmatic criteria: 
(1) those with the greatest harm and least benefit; 
(2) those easiest to discontinue, ie, lowest likelihood of withdrawal reactions or disease rebound; 
(3) those that the patient is most willing to discontinue first (to gain buy-in to deprescribing other 
drugs) 
- Suggested approach is to rank drugs from high harm/low benefit to low harm/high benefit and 
discontinue the former in sequential order 
5. Implement and monitor drug 
discontinuation regimen 
- Explain and agree with patient on management plan 
- Cease 1 drug at a time so that harms (withdrawal reactions or return of disease) and benefits 
(resolution of adverse drug effects) can be attributed to specific drugs and rectified (if necessary) 
- Wean patients off drugs more likely to cause adverse withdrawal effects, instruct patient (or 
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carer) on what to look for and report in the event of such effects occurring, and what actions they 
can self-initiate if these were to occur  
- Communicate plan and contingencies to all health professionals and other relevant parties 
(carers, family) involved in patient’s care 
- Fully document the reasons for, and outcomes of, deprescribing 
 
From Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, Gnjidic D, Del Mar CB, Roughead EE, Page A, Jansen J, 
Martin JH. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827-34. 
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While the process proposed by Scott, et al, suggests multiple possible questions to 
identify drugs that are candidates for deprescribing (step 3 in the process), there are existing tools 
that could be employed in this step. For example, to identify drugs that are contraindicated in 
certain groups, that have well-known adverse effects, or are either unlikely to cause benefit or 
the benefit is outweighed by harm, explicit lists such as the Beers criteria or the Screening Tool 
of Older Persons’ Prescriptions could be used to determine drugs eligible for deprescribing.20,21 
Scott also proposes an algorithm to determine the order and the mode by which medications 
could be discontinued.  
 
Patient preferences for deprescribing 
 The process of deprescribing requires active assessment of patients’ attitudes and 
preferences along the way. For example, patients should be asked whether they think a 
medication is helpful, if it causing side effects or burden and, ultimately, if they prefer to 
continue it. Medications that are eligible to be deprescribed and that a patient is willing to stop 
should be prioritized for deprescribing first, in order to gain patient buy-in and trust during the 
process.
19
 
In adults with multimorbidity, in whom benefits and risks of medication therapy are 
uncertain, and benefits or risks of stopping medications are also uncertain, deprescribing could 
be considered a preference-sensitive decision, in which patients’ goals and preferences for care 
should be highly influential in the decision-making process.
1
 Identifying medications that are 
eligible to be deprescribed may be based on an inappropriate benefit-risk ratio, in addition to the 
complexity and feasibility of the medication regimen, and the alignment with goals and 
11 
 
preferences for care. A proposed framework to identify candidate drugs to stop in such patients is 
shown in Figure 2.
22
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Figure 2. Problems with medications in patients with multimorbidity, reprinted with 
permission from Fried TR, Niehoff K, Tjia J, Redeker N, Goldstein MK. A Delphi process to 
address medication appropriateness for older persons with multiple chronic conditions. BMC 
Geriatr. 2016;16(1):67. Epub 2016/03/17. doi: 10.1186/s12877-016-0240-3. 
 
What do patients think about deprescribing? Surprisingly, few qualitative studies have 
specifically explored patients’ attitudes toward deprescribing. A study of the perspectives of 
long-term care residents and healthcare professionals suggested that to be successful, 
deprescribing interventions need to take into account the perspectives of multiple stakeholders.
23
 
For residents in particular, highly ranked concerns included their well being, continuity of care 
and communication, the ability to continue medications that contributed to their feeling of 
wellness, the ability to stop medications they believed to be burdensome, having their voices and 
rights respected, and respecting the opinions of their physicians.
23
 A study of frail long-term care 
residents and healthcare professionals in Australia found a significant disconnect between the 
perceptions of medication benefits on the part of residents and their family members, whereas 
physicians recognized that for frail older patients, long-term care was essentially palliative.
24
 In 
addition, residents had poor understanding about the indications and possible adverse effects of 
their medications, low self-efficacy around medication discontinuation, and high trust in their 
physician to make medication decisions.
24
 Similarly, a study of 85 patients with heart failure and 
74 prescribing physicians found a disconnect regarding deprescribing; most of the patients were 
not dissatisfied about the number of medicines they took regularly, and only 41% could identify 
at least one drug they would stop, whereas physicians had a high consensus about drugs that 
could be stopped when presented with clinical heart failure scenarios.
25
 In contrast, a study 
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exploring the medication-related views of patients with life-limiting illness as well as their 
caregivers found that there was acknowledgement that medications were burdensome, and there 
was a willingness to rationalize medication use, particularly when they were exposed to 
polypharmacy.
26
 Patients and caregivers also recognized that a transition in care, potentially after 
the diagnosis of life-limiting illness, was a time when less importance was placed on taking 
preventive medications, with a willingness to change medications at such transitions.
26
  
Trials associated with deprescribing interventions have not consistently explored patient 
preferences, perceptions or experiences. A recent systematic review included 21 randomized 
controlled trials (RCTs) on deprescribing specific drugs (rather than an overall approach to 
reducing medication number), including antipsychotics, diuretics, antidepressants, digoxin, 
statins, and drugs for benign prostatic hyperplasia. They found that in many of the trials, 
deprescribing medications led to a relapse or worsening of symptoms or the underlying disease 
state. The review did, however, not specifically address patient preferences or patient-specific 
outcomes.
16
 In a trial of stopping proton pump inhibitors (PPIs), of 72 patients considered for 
PPI withdrawal, 8 were considered appropriate to deprescribe, 6 consented, of whom 3 stopped 
the drug and 3 reduced the dose. Three of the 6 participants returned feedback and reported that 
they were comfortable with the process and willing to have another medication similarly 
deprescribed.
11
 A cross-sectional study of patients in the last few days of life in a geriatric ward 
in Belgium found that deprescribing of inappropriate medications at the end of life was more 
frequent if death was expected, and the authors noted further opportunity to optimize medication 
use by deprescribing drugs at the end of life. They particularly noted that in cases where 
prognostication is difficult, early discussions of patient’s preferences and wishes for end of life 
care could help to engender trust with the physician and facilitate the process of deprescribing 
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life-long medications at the end of life.
27
 This is in agreement with a recently published set of 
recommendations around deprescribing approaches in limited life expectancy that outline the 
importance of patient-centered, shared decision-making.[ref our paper] 
To specifically address patients’ willingness to undertake deprescribing, Reeve, et al. 
developed the Patients’ Attitudes Towards Deprescribing questionnaire.28 The PATD was then 
employed in an ambulatory setting in a sample of adults, 65% of whom were over 65 years old, 
and 92% reported willingness to have one or more medications stopped.
29
 The PATD was 
applied in a population of older hospitalized patients in Italy, and found that most of the patients 
felt that they were taking too many medications, and 89% were willing to have one of their 
regular medicines deprescribed.
30
 The PATD was also applied specifically around stopping 
statins on older inpatients in Australia, and found that 89% of the participants were willing to 
stop one or more of their regular medications, and 95% were willing to stop statins.
31
 
Patients’ willingness to deprescribe may not be enough. Indeed, based on results from 
qualitative studies highlighting the need for more communication and a focus on patient well 
being, and based on quantitative studies showing lower uptake of deprescribing interventions and 
concerns for relapse of underlying symptoms, a successful deprescribing intervention must seek 
to fully engage both the patient and, where relevant, the caregiver. The EMPOWER trial is an 
example to describe such an approach: this intervention was developed  toward increasing 
patients’ knowledge and self-efficacy around stopping benzodiazepines, and was designed to 
create a cognitive dissonance around the perception that harmful medications were safe.
32
 The 
intervention consisted of a booklet with an assessment about medication risks, education about 
harms and drug interactions, and a specific step-wise tapering protocol. Overall, 86% completed 
a 6-month follow up, at which point 27% of the intervention group had stopped the 
15 
 
benzodiazepine, compared to only 5% of the control group (who received general educational 
materials). This approach has been expanded to other classes of drugs, with publicly available 
deprescribing algorithms for practitioners to employ.
33
 
Barriers and pitfalls to deprescribing 
Despite the perceived acceptability of deprescribing and the momentum toward reducing 
medication use, there are significant barriers to stopping medications. The biggest barrier to 
deprescribing is an emotional and psychological one: our belief as a society and healthcare 
system that every patient-doctor interaction needs to end in the addition of a medication, and that 
additional medication will either prolong life or promote health.
34
 Much has been written about 
prescribers’ discomfort in stopping medications, and emerging discussion of these barriers 
incorporates a consideration of patient and system barriers to the process.
35
 While there is a 
disconnect between patients and prescribers regarding the belief about the benefit of 
medications, the widespread dislike of overmedication is a major enabler of deprescribing as an 
acceptable intervention.
35
 Recent evidence regarding the willingness of patients to stop 
medications and their reliance on physicians to communicate the need to stop drugs puts the onus 
back on prescribers to take on responsibility to make deprescribing more commonplace.
18
 The 
barriers to deprescribing are summarized in the Box.  
Box. Potential Barriers to Deprescribing
18,23,35-37
 
 
Prescriber Lack of guidelines, lack of decision support 
Lack of time 
Fixed beliefs about benefits and harms of medications 
Lack of awareness; incomplete medical or medication history 
16 
 
Clinical inertia 
Lack of knowledge or skills 
Beliefs about external constraints  
Need for multiple points of contact/communication to deprescribe 
Reluctant to change specialists’ medications 
Patient Lack of decision making capacity 
Difficulty in comprehension or communication around deprescribing 
Need for caregiver engagement 
Misalignment with goals of care 
System Lack of reimbursement  
Fragmentation during transitions of care 
Lack of facilitators for communication 
Absence of integrated electronic medical records system across different sites 
Discoordinated care 
 
Prescribers’ opinions vary widely, particularly about preventive medications, highlighting 
the need for consensus guidelines around deprescribing.
12
 The optimal time at which to 
deprescribe, the ideal patient situations in which deprescribing should occur, and the ideal 
settings are unclear and may very widely based on the individual clinical situation. For example, 
while transitions of care may represent an ideal time to reconcile and critically rethink all 
medication therapy, deprescribing in the hospital could be a problem for sustaining change. 
Deprescribing requires active participation of the patient, including communication and 
agreement to the change, and an acutely ill patient may not be able to participate in 
17 
 
deprescribing.
38
 Similarly, the ideal patient situations that should prompt deprescribing are 
uncertain. As an example, patients with dementia may have frequently changing goals of care, 
making deprescribing necessary as care shifts at the end of life; however, the inability to engage 
the patient in deprescribing and the need to engage caregivers with frequent communication may 
present obstacles.
36
  
Ultimately, addressing these specific barriers could help to facilitate deprescribing and 
make stopping medications as facile as prescribing them in the first place. This could be 
accomplished by a number of changes, not the least of which includes: 
1) Systematically screen patients for their willingness to have medications deprescribed. Much 
in the same way that providers systematically screen for depression or for falls, tools such as 
the PATD could be employed to elicit a patient’s attitudes, which could help inform 
providers about preferences and could facilitate patient-centered decision-making about 
medicines.
28
 
2) Provide health information systems that facilitate communication between multiple 
specialists and with the patient and caregiver, to reduce the concerns about stopping 
medicines that other prescribers have started. 
3) Leverage data systems to identify medications that are eligible for deprescribing or patients 
that are ideal candidates for deprescribing interventions.
39
 This could be accomplished 
through the use of existing tools to identify inappropriate medications and tools to identify 
patients with high-risk conditions. 
4) Promote reimbursement for deprescribing activities by members of a multidisciplinary team, 
and specifically facilitate the input of pharmacists in making recommendations to 
deprescribe. 
18 
 
5) Strengthen the evidence based around deprescribing by including patient goal-driven 
interventions and patient-reported outcomes in deprescribing studies.  
Conclusions 
Deprescribing is more complex than simply stopping medications: it is a multiple stage 
process that should be patient-centred and a part of the wider remit of shared care decision-
making.  Despite the acknowledgment that patient preferences – alongside those of healthcare 
professionals and caregivers – are crucial for any successful deprescribing intervention there is, 
at present, a dearth of literature in this area.   Future studies – particularly randomized controlled 
trials – should be encouraged to include a qualitative aspect to enable the better understanding of 
perceptions and experiences for patients who have undergone deprescribing interventions.  It will 
be crucial for future deprescribing interventions to be able to adapt to new evidence as it emerges 
and still allow for the application of clinical judgment and the consideration of ethical issues. 
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